From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

References

• Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res.12(2), 134–141 (1952).
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA294(2), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs9(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• De Bono J, Logothetis C, Fizazi K et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled Phase III study. Ann. Oncol.21(Suppl. 8), VIII1–VIII12 (2010) (Abstract).
   Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI. Technology evaluation: APC-8015, Dendreon. Curr. Opin. Mol. Ther.4(1), 76–79 (2002).
   PubMed Web of Science ®Google Scholar
• Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother.42(1), 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res.6(6), 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol.18(23), 3894–3903 (2000).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs18(7), 1001–1011 (2009).
   PubMed Web of Science ®Google Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther.4(4), 575–588 (2004).
   PubMed Web of Science ®Google Scholar
• Kaufman H, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.22(11), 2122–2132 (2004).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res.59(22), 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res.62(20), 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res.61(11), 4497–4505 (2001).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol.178(4 Pt 1), 1515–1520 (2007).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother.59(5), 663–674 (2010).
   PubMed Web of Science ®Google Scholar
• Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp. Biol. Med.233(5), 522–534 (2008).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol.8(1), 59–73 (2008).
   PubMed Web of Science ®Google Scholar
• Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs14(10), 833–843 (2003).
   PubMedGoogle Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res.11(18), 6713–6721 (2005).
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol.26(36), 5950–5956 (2008).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Stein WD, Figg WD, Dahut W et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist13(10), 1046–1054 (2008).
   PubMed Web of Science ®Google Scholar
• Fojo A, Stein W, Wilkerson J, Bates S. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J. Clin. Oncol.28(15s), 1096 (2010) (Abstract).
   Google Scholar
• Wilkerson J, Stein W, Kim S et al. Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-α (IFN-α): Analysis of the pivotal randomized trial. J. Clin. Oncol.28(15s), 4597 (2010) (Abstract).
   Google Scholar
• Stein WD, Gulley J, Schlom J et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin. Cancer Res.17(4), 907–917 (2010).
   PubMedGoogle Scholar
• Gulley J, Stein W, Schlom J et al. A retrospective analysis of intramural NCI prostate cancer trials: progress made and insights gleaned. J. Clin. Oncol.28(15s), 4657 (2010) (Abstract).
   Google Scholar
• Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J. Urol.176(6 Pt 2), S72–S75 (2006).
   Google Scholar
• Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer71(Suppl. 3), 1098–1109 (1993).
   PubMed Web of Science ®Google Scholar
• Scher H, Chi K, De Wit R et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (pts) with progressive castration-resistant prostate cancer (CRPC): results from the Phase III ASCENT2 trial. J. Clin. Oncol.28(15s), (2010) (Abstract 4509).
   Google Scholar
• Kelly W, Halabi S, Carducci M et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol.28(18s), (2010) (Abstract LBA4511).
   Google Scholar
• Small E, Demkow T, Gerritsen W et al. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Program and Abstracts of the Genitourinary Cancers Symposium. Orlando, FL, USA (2009) (Abstract 7).
   Google Scholar
• Sartor A, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational Phase III trial (TROPIC). Program and Abstracts of the Genitourinary Cancers Symposium. San Francisco, CA, USA (2010) (Abstract 9).
   Google Scholar
• Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.26(28), 4563–4571 (2008).
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.28(9), 1496–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin. Investig. Drugs19(4), 563–570 (2010).
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol.21(7), 1232–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin. Biol. Ther.10(1), 19–28 (2010).
   PubMed Web of Science ®Google Scholar
• Higano CS, Corman JM, Smith DC et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer113(5), 975–984 (2008).
   PubMed Web of Science ®Google Scholar
• Fu T, Shen Y, Fujimoto S. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J. mice. Int. J. Cancer87(5), 680–687 (2000).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol.34(2), 336–344 (2004).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA102(51), 18538–18543 (2005).
   PubMed Web of Science ®Google Scholar
• Kawaida H, Kono K, Takahashi A et al. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res.124(1), 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.61(12), 4766–4772 (2001).
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol.167(3), 1137–1140 (2001).
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol.168(9), 4272–4276 (2002).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol.155(3), 1151–1164 (1995).
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin. Biol. Ther.2(8), 827–834 (2002).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell101(5), 455–458 (2000).
   PubMed Web of Science ®Google Scholar
• Madan R, Vergati M, Cereda V et al. Changes in regulatory T cell function and overall survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with a vector-based vaccine. Presented at: AACR Annual Meeting. Denver, CO, USA, 18–22 April 2009 (Poster 726).
   Google Scholar
• Vergati M, Cereda V, Madan RA et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol. Immunother.60(2), 197–206 (2010).
   PubMedGoogle Scholar
• Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol.26(15), 2544–2549 (2008).
   PubMed Web of Science ®Google Scholar
• Higano C, Saad F, Somer B et al. A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Program and Abstracts of the Genitourinary Cancers Symposium. Orlando, FL, USA (2009) (Abstract LBA150).
   Google Scholar
• von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res.7(5), 1181–1191 (2001).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res.13(21), 6396–6403 (2007).
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol.26(7), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res.14(14), 4526–4531 (2008).
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 479–481 (2010).
   PubMed Web of Science ®Google Scholar
• Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol. Immunother.59(3), 397–408 (2010).
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol.27(25), 4047–4054 (2009).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol.174(6), 3798–3807 (2005).
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front. Biosci.12, 4957–4971 (2007).
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell7(3), 239–249 (2005).
   PubMed Web of Science ®Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res.14(11), 3536–3544 (2008).
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res.64(12), 4328–4337 (2004).
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst.102(18), 1388–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Ateeq B, Kalyana-Sundaram S et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med.16(7), 793–798 (2010).
   PubMed Web of Science ®Google Scholar
• Sharifi N, Hamada A, Sissung T et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int.102(5), 617–621 (2008).
   PubMedGoogle Scholar
• Kantoff P, Higano CS, Berger ER. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). Programs and Abstracts of the 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA (2010) (Abstract).
   Google Scholar